InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-18.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Piper Brian, Chief Financial Officer. Insider active across 1 company, notably Prelude Therapeutics Inc. Cumulatively, 4 disclosures have been recorded. Activity tracked since 25 May 2021. The latest transaction was filed on 25 August 2021 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations4 total
8,333 shares@ US$1.890.0037% mcap25.5% of flowCommon StockSEC:0001209191-21-053758:0
8,333 shares@ US$1.8925.5% of flowCommon StockSEC:0001209191-21-053758
8,333 shares@ US$1.890.0036% mcap24.5% of flowCommon StockSEC:0001209191-21-036297:0
8,333 shares@ US$1.8924.5% of flowCommon StockSEC:0001209191-21-036297
4 of 4 declarations
About Piper Brian
Brian Piper is the Chief Financial Officer at Prelude Therapeutics Inc. He is responsible for the financial management of the company, including budgeting and performance analysis. With extensive experience in finance, he plays a key role in financial strategy and decision-making. His commitment to transparency and compliance is essential for Prelude's success.
